PTC Therapeutics PTCT RU — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's ru — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's RU — revenue?
- PTC Therapeutics (PTCT) reported RU — revenue of $3.25M in Q1 2026.
- How has PTC Therapeutics's RU — revenue changed year-over-year?
- PTC Therapeutics's RU — revenue decreased by 91.6% year-over-year, from $38.51M to $3.25M.
- What is the long-term trend for PTC Therapeutics's RU — revenue?
- Over 2 years (2023 to 2025), PTC Therapeutics's RU — revenue has grown at a 8.1% compound annual growth rate (CAGR), from $85.97M to $100.45M.
- What does RU — revenue mean?
- This metric represents the total net revenue generated from product sales or services within the specified geographic or operational segment, excluding any taxes assessed on the transaction. It serves as a primary indicator of the segment's commercial performance and market penetration for the company's therapeutic portfolio. By isolating this revenue stream, investors can evaluate the growth trajectory and demand for the company's biopharmaceutical products in this specific region.